Androgen Receptor (AR) induced precocious myogenesis in culture and myogenic specified gene activity. Increased levels of AR expression in replicating C2C12 myoblasts stimulated fusion into post-differentiated multinucleated myotubes and the appearance of skeletal α-actin transcripts, even in the absence of ligand. Furthermore, AR activated the skeletal α-actin promoter, which lacks GRE sites, in co-transfected C2C12 cells. AR coactivation of the skeletal α-actin promoter required co-expressed full length SRF. In vitro, AR associated with SRF and was recruited by SRF to a α-actin promoter SRF binding site. Our data suggest that AR is capable of activating myogenic genes devoid of consensus AR binding sites via its recruitment by the myogenic enriched transcription factor, SRF.
Steroid androgens play an important role in determining lean body mass and muscle strength. For example, men made hypogonadal lose lean body mass and muscle strength (1) , while in older men, decrements in circulating testosterone levels correlates well with reduced musculature (2) . In addition, treatment of hypogonadal men or older men with androgens elicited increased muscle strength and lean body mass (3, 4) . Androgens used by healthy young athletes and weightlifters (5) maximize muscle mass and strength. Testosterone increased maximal voluntary strength in a dose-dependent manner (6, 7) and was shown to be a limiting factor in muscle strength development (8) , during training-induced muscle hypertrophy (9) . Androgens used as a treatment for cachexia, also increased fat-free muscle mass and maximum voluntary strength (10) . Thus, there is strong evidence that androgens increase muscle mass and strength, both under pathological and physiological conditions.
Most studies conducted to date have focused on the positive role of androgens on skeletal muscle protein synthesis (11) (12) (13) . The molecular basis of myogenic enhancement by androgens is not well understood (6, 7, 14) . The androgen receptor (AR), (15) is a member of the Zinc Finger Class of transcription regulators, and the steroid and thyroid hormone receptor superfamily (16) . AR binds androgens by a discrete domain at the 250 c-terminal amino acids of its' primary structure (17, 18) and upon binding undergoes phosphorylation (19) and a conformational change. Proteins with the capacity to retain the receptor in the cytoplasm are dissociated and AR nuclear localization signals become exposed allowing for nuclear entry and transcription activation (20) . Nuclear hormone receptors are divided in two families, in regard to the DNA sequences they recognize. Estrogen, thyroid and retinoid acid receptors recognize ERE-like (AGGTCA) sequences, while androgen, glucocorticoid and progesterone receptors recognize GRE-like (AGAACA) sequences (21) (22) (23) . To date, there are no known direct AR DNA targets that drive myogenic specified genes (6) . AR, as well as other members of the nuclear receptor superfamily, is modulated by coregulatory proteins. (24) . Steroid receptors have been shown to interact with other DNA-binding proteins, resulting in modulation of steroid receptor transcriptional activity. AR has been found to interact with a number of transcription factors including AP-1 (25), Smad3 (26, 27) , nuclear factor kappa B (NF κB) (28, 29) , sex-determining region Y (SRY) (30) , and the Ets family of transcription factors (31) . A feature of a large number of myogenic expressed genes is their dependence upon high affinity binding sites for serum response factor (SRF). SRF shares a highly conserved DNA-binding/dimerization domain of 90 amino acids, termed the MADS box. SRF serves as a versatile protein that binds to its cognate sites in a multitude of promoters to integrate intracellular signals and assists as a docking surface for the binding of accessory factors that may confer the regulation of specific gene programs (32) (33) (34) (35) (36) (37) . SRF is a key regulator of immediate early gene expression, which frequently results in mitogenesis, and also of myogenic terminal differentiation. Many muscle-specific genes, including skeletal, cardiac and smooth muscle α−actins contain combinations of at least three or more strong and weak affinity SREs (SRE: serum response element) that bind SRF in a highly cooperative manner. (37) (38) (39) . Accessory factors may then play essential roles in either facilitating or impeding SRF binding on multi-SRE muscle gene promoters; thus, stimulating or repressing transcription of SRF dependent gene targets. Recently, Kim et al (40) showed that the steroid receptors, RXR and or RAR, physically associated with SRF and repressed SRF dependent c-fos transcriptional activity. We asked if AR played a similar role in myogenesis, and whether it also functioned as an SRF cofactor. Herein, AR activated the skeletal α−actin promoter, which lacks GRE sites, in co-transfected C2C12 cells and provided androgen regulation over the αSk-actin promoter. AR was observed to associate with SRF and together were recruited to SRF DNA binding elements (SRE). Thus, AR was capable of activating a myogenic gene devoid of consensus AR binding sites via its recruitment by SRF. AR also induced precocious muscle differentiation in culture and acted as a potent activator of myogenic gene activity.
Materials and Methods
Cell culture -C2C12 mouse myoblasts were purchased from American Tissue Culture Collections. Myoblasts were maintained at 37C, 5%CO2 in a humidified incubator, in Dulbeccos' Modified Eagles Medium, supplemented with 20% neonatal calf serum. CV1 green monkey kidney fibroblasts were purchased from American Tissue Culture Collections and maintained at 37C, 5%CO2 in a humidified incubator, in Dulbeccos' Modified Eagles Medium, supplemented with 10% fetal calf serum. DNA plasmids -Expression vectors for hAR (human Androgen receptor )-mutants have been previously described (17) . Vector encoding hAR (human AR) wildtype was used via PCR to subclone hAR into pCGN vector (41) for mammalian expression and into Bluescript (Stratagene) for transcription/translation by reticulocyte lysates. In detail. Construction of pCGNhAR. 5'Primers: 5'GGACCTTCTAGAGAAGTGCAGTTAG GG CTGGGA3' and 3' primer 5'GCGTGTGGATCCTCACTGGGTGTGG AAATAGATGG3'. Human Androgen Receptor from the plasmid pAR0 (17) was PCR amplified using the above primers. The PCR product was agarose gel-purified, digested with XbaI and BamHI, and ligated to PCGN vector that had been digested with the same enzymes. Construction of Bluescript-hAR. 5'Primer. 5'GGACCTTCTAGAATGAGTGCAGTTA GGGCTGGGA3' and the 3'Primer 5'GCGTGTGGATCCTTTATTTCACTGG GTGTGGAAAT AGATGG3'. Oligonucleotide primers were used to amplify hAR from pAR0 and ligate to plasmid pBluescript KS (+), after digestions with BamHI and XbaI. hARLBD (ligand binding domain) from pcDNA3 was cut with HindIII and XbaI, and ligated into pP(A)LiS(MS-2) that was cut with those two enzymes. This gave rise to pP(A)LiSKhAR-LBD, which we used for Sp6-driven ARLBD transcription. SRF mutants cloned in the vector pCGN have been described elsewhere (42) . pCGN-SRF wildtype and pm1 were kind gift from Ron Prywes. pGEX Plasmids encoding fusions of hAR truncations with GST (glutathione-Stransferase) have been described elsewhere (43) . Plasmid MMTV-Luc was a kind gift from Dr Ben Peeters (44) . Plasmid with the sequence -398 to +25 of the avian skeletal α−actin promoter cloned upstream of the firefly Luciferase gene is described elsewhere (45) .
Analysis of skeletal α−actin expression -C2C12 myoblasts were plated on 100mm plates at a density of 10 6 cells/well. Myoblasts were first cultured in growth medium (GM) which was switched after 24 hours to differentiation medium (DM).
Myogenic cells were either treated with 50nM of the synthetic androgen R1881 (NEN)/ml culture medium or control dilutant. After indicated times, cells were harvested in Trizol (Invitrogen) and assayed by standard RNA blotting using a probe specific for the 3' untranslated region of the skeletal alpha actin gene (46) using previously described conditions (47) . The probe used Mouse α−skeletal 3' UTR (196bp)-(ref. 48 ) was cut with EcoRI and HindIII, gel purified. Labeled were 10ng with Amershams' kit ("Ready to go") and 32 PdCTP from ICN. Transfection assays -Cells were seeded in 24-well plates at a density of 35,000 cells per well and left overnight. The next day, transfections were carried out with 2.5µl Lipofectamin (Invitrogen) according to manufacturers' instructions. Expression vectors were used at 0.4µg/well; reporter at 0.2µg/well. Cells were harvested in cell lysis buffer (Promega) 48 hours after transfection, and assayed using luciferase substrate as described previously (45, error bar: SD: standard deviation). For stable transfection, we used human Androgen Receptor cDNA, subcloned in the CMVdriven vector pCGN (41) , which confers a Hemagglutinin Tag, to express AR in stably transfected C2C12 myoblasts ( Fig 1A) . For this purpose, we transfected C2C12 cells with either pCGN vector containing the hAR cDNA insert, or pCGN vector devoid of insert. We included a twenty-fold lesser amount of vector pCMV-Neo, which encodes for the selectable trait of Geneticin ("G418") resistance. After at least two weeks in selective medium, we pooled and expanded surviving cells. C2C12 myoblasts plated at a density of 1 × 10 6 cells/100-mm tissue culture dish in growth medium were co-transfected with 20 µg of pCGN or pCGN-hAR and 1 µg of pCMVneo selection plasmid in a DNA Lipofectamin mixture.
After overnight incubation, myoblasts were allowed to recover, split 1:20 with fresh growth media, and then challenged in selection media (400 µg/ml G418 from Invitrogen). Cells were selected approximately 10-14 days following the addition of selection media, and were evaluated by harvesting in SDS sample buffer and analysis by western as follows: 3x10 5 C2C12 myoblasts stably transfected either with pCGN or with pCGN-hAR, growing on 60mm plates, were taken up in SDS (sodium Dodecyl sulfate) sample buffer. Aliquots were loaded on an SDS PAGE (polyacrylamide gel electrophoresis) gel, and transferred onto an Immobilon-P membrane (Millipore). Other aliquots loaded on SDS PAGE were visualized with Coomassie stain to see comparative protein loads.The membrane was assayed by immunobloting for the hemagglutinin-tagged hAR, using anti-HA antibody (clone 12CA5 Roche) according to manufacturers' instructions at the dilution 1:100, and secondary anti mouse antibody from Biorad (catalog number 170-6516).
For cell differentiation assay, C2C12 myoblasts were plated on six-well plates at a density of 10 5 cells/well. After 24 hours cells were washed with PBS and transferred to charcoal-stripped DMEM (Dulbeccos' modified Eagles' medium) & 2% horse serum. After 24, 48, 72, 96 hours, cells were viewed by an Olympus IMT 2-F microscope and photographed using an Olympus OM88 camera. GST fusions of AR or SRF were expressed in bacteria Escherichia Coli BL21-Gold (DE3) (Stratagene), and bacteria were broken by sonication. After pelleting debris, aliquots of the supernatants were taken to isolate GST-fusions using Glutathione-Sepharose beads (Pharmacia) according to the manufacturers' instructions. After 3 washes, supernatant aliquots were loaded on an SDS page gel, and visualized by Coomassie staining. Rest was used in binding assays, by incubating with 20µl of reticulocytetranslated 35 S-labelled SRF.
After five washes with phosphate buffered saline, pellets were taken up in SDS sample buffer and analyzed by SDS PAGE via autoradiography to detect 35 S-labelled SRF or AR. GST-fused protein loading was analyzed by coomasie stain, while labelled proteins were visualized by loading 10% of input.
In vitro transcription-translation of proteins was carried out with the kit TNT (Promega), using the manufacturers' instructions. For coimmunoprecipitations C2C12 myoblasts stably transfected with hAR were harvested in lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 300 mM KCl, 5% (v/v) glycerol, 0.5% (v/v) Triton X-100, 1 mM benzamidine, 2 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, and 2 µg/ml aprotinin). Cells were lysed for 1 h at 4 °C, and the C2C12 soluble lysate was mixed with non-immune sera or polyclonal rabbit IgG anti-hAR specific for the AR C-terminous (Santa Cruz Biotechnology, Inc.) or 2 µg of normal rabbit serum IgG bound to 10 µl of protein A-Sepharose beads for 2 h at 4 C. The beads were then washed three times in immunoprecipitation buffer, washed once in PBS, eluted in SDS-PAGE sample buffer, and run on 10% SDS-PAGE gels under reducing conditions. DNΑ−affinity precipitations were carried out as described by Chen & Schwartz (33) , using 25µl of reticulocyte-translated protein for each reactant. SRF binding sites (used with their complementary oligonucleotides, after boiling and overnight return to room temperature, to form double strands): SRE3: biotin-5'-GGACGCTCCTTATACGGCCCGG-3'; SREmt:biotin-5' GGACGCTaaTTATACGG CCCGG-3'.
RESULTS

Increased expression of the human androgen receptor in C2C12 myoblasts enhanced terminal myogenic differentiation.
Human androgen receptor, a member of the family of steroid binding nuclear receptors (16) , has DBD (DNA binding domain) and LBD (Ligand binding domain) domains identical to those of mouse and rat (49) while the Nterminal domain and hinge region are also highly conserved.
We asked if stably transfected pCGN-hAR, would affect differentiation of cultured murine C2C12 myoblasts.
hAR myoblasts formed myotubes precociously and to an overwhelming extent, when compared to myoblasts transfected with the empty pCGN vector (Fig 1A) . In particular, as shown in Figure 1A , after 48 hr hAR-transfected cell clones had already started to convert to multinucleated myotubes, while vector-only cells were just initiating differentiation.
Skeletal α−actin (αSk) is a major component of differentiated striated muscle (46, 50) in the adult vertebrate and appears post-replication and after fusion in terminally differentiated myogenic cultures. In growth media, C2C12 stable hAR transfectants, barely induced the appearance of aSk mRNA over control myoblasts. However, following a switch to differentiation media, we observed robust appearance of αSk transcripts and myoblast fusion, in hAR transfected C2C12 cells, independent of exogenous androgen ligand, R1881. We have observed that αSK appeared approximately 96 hours postplatting of myogenic cultures (51), as observed in Figure 1B . Thus, addition of hAR caused precocious induction of a terminal differentiation marker, αSk, within 48hr of plating myoblasts stably transfected with hAR, in contrast to control myoblasts containing empty vector (Fig 1B) . These results revealed a profound role for AR in early myogenesis and indicated that αSk is an AR gene target. Figure1C shows a 10% PAGE and anti-SRF blot of soluble extracts taken from the stable transfected C2C12 cultures; indicating association of SRF with hAR protein, as SRF expression is induced by the transfer of myoblasts in differentiation medium.
Skeletal actin gene promoter is activated by AR in an SRF-dependent fashion. We determined that there were no consensus DNA recognition sites for AR on the αSk-actin promoter (-398 to +25 nt; described in 45), employing the program TFSEARCH set at reduced default settings to a score of 70 (52, 53) . Since other closely related members of the steroid family were shown to interact with SRF, we asked if AR might also require cofactors such as SRF to transactivate the αSK-actin promoter. In proliferating C2C12 cells (low in SRF, ref. 39, 54) , neither expression of SRF or AR alone appreciably increased reporter activity. The presence of the synthetic androgen, R1881 and SRF increased luciferase activity by 7.5 fold (Fig 2A) , when compared to pCGN. However, transient co-transfection experiments with hAR and SRF expression vectors with the αSk-actin promoter luciferase reporter gene revealed synergistic co-activation of AR with SRF in prefusion C2C12 myoblasts ( Fig. 2A) by increasing promoter activity by 22 fold. The addition of R1881 to SRF and AR cotransfected myoblasts stimulated αSk-actin promoter transcription up to 98 fold over pCGN levels, thus, showing dependency for full activation on the addition of exogenous androgens.
SRF is a protein of 550 amino acids. 141-222 comprise a DNA binding and dimerization domain (referred to as MADS box), while the carboxy terminus, including amino acids 384-448, has transactivation function (42) . We made several truncated SRF proteins to define the domains of SRF that may be required for co-activation with AR. We used cells devoid of appreciable SRF (42) or AR (19) expression: coactivation of promoter activity was observed in co-transfected CV1 fibroblasts (Fig. 2B) . Only full length SRF was able to cooperate with AR in activation of αSk-actin promoter. All mutants of SRF had in the presence of AR lower transactivation potential than alone. Absence of SRE and thereby DNA-bound SRF abrogates induction of the promoter.
Recruitment of Androgen Receptor by SRF on intact SRE. We next investigated whether SRF could selectively recruit AR protein in the cellular lysate containing SRF binding sites. The SRE3, a site essential for full activity of the skeletal Actin Promoter, located between -186 to -167 bp. (55), was biotinylated and precipitated using Avidincoated magnetic beads. The bound material was eluted and analyzed by SDS-PAGE. We show that AR is specifically recruited by SRE3 only in the presence of SRF (Fig 3) . This demonstrates the possibility of a physical association of hAR with DNAbound SRF. Our results indicate that SRF and AR are able to establish protein-protein contacts in solution and AR protein is recruited to the SRF DNA binding site; it is unlikely that both proteins interact with each other by non-specific aggregation.
Wildtype AR is required for androgen dependent skeletal actin promoter activity. We asked if any of the AR protein domains (17) were required for regulating aSk-actin reporter activity under differentiation conditions. In these experiments myogenic differentiation induces the appearance of SRF (54), thus, the addition of SRF expression vectors was viewed as being redundant and were not included in the assays. After switching to differentiation medium, Figure 4A showed aSk-actin promoter activity was stimulated by transient co-transfection of full length AR and required the presence of synthetic androgen, R1881. Removal of the ligandbinding domain provided activity similar to the wildtype AR, but was insensitive to exogenous androgen. Removal of the AR activation domain (AR528-910) also prevented αSK promoter activation by steroid. It is interesting to note that cotransfection of C2C12 myoblasts with MMTV-Luc reporter and wildtype and mutated AR expression vectors showed that wildtype AR caused robust transactivation dependent on androgen while deletion of the LBD caused MMTV activation independent of exogenous R1881. Other mutations in regions that surround the activation domain or which partially delete the activation domain still allowed for MMTV promoter activation a promoter containing AR binding sites (44) to wildtype AR levels (Fig 4B) . Thus, the loss of androgen-dependent activation of the αSk-actin promoter activity by the AR mutants (Fig 4A) cannot be explained by a deficiency in their transactivation potential, but may be explained by weakened association with SRF. Also, judging from the fact that AR mutants contained intact DNA binding domain, it must be concluded, that αSk-actin does not behave like a target of direct AR DNA binding, but requires parts of AR protein distinct from those that induce MMTV activity, to work with SRF. Since the AR truncations displayed deficient activation of skeletal alpha actin promoter, at least two AR domains are expected to interact with SRF.
Identification of SRF interacting domains in hAR
Which domains of AR protein are necessary for SRF interaction? We used glutathione-coated sephadex beads to precipitate portions of the AR protein linked to GST (43) , by incubating them in the presence of reticulocyte-translated, 35 Slabeled SRF. Domains with a selectively higher affinity for SRF ought to recruit SRF to the beads. We analyzed the results by taking aliquots of precipitated, washed beads in SDS PAGE buffer and subsequent electrophoresis. Coomasie stain was used to visualize GST-fused AR domains, while AR-recruited, labelled SRF was visualized by autoradiography. Multiple GST fused-AR domains were capable of interaction with SRF (Fig 5) . This hints to multiple contacts between the two proteins, and explains why in transfection experiments (Fig 4) When we carried out the converse experiment, 35 S-labelled AR was strongly recruited by GST-fused wildtype SRF, but to a far lesser extent by SRF mutants (Fig  6) . Since all data indicated that SRF and AR make more than one interdomain contact, we assayed GST-fused SRF (wildtype and mutants) for recruitment of 35 S-labelled AR LBD or AR 1-370 (Fig 7) . The binding study indicates that the SRF N-terminal sequences, including the α1-coil of the MADS box, recruited AR LBD, while SRF constructs containing C-terminal sequences bound to AR 1-370.
DISCUSSION
Detailed mechanisms by which the androgen-AR signaling pathway regulates skeletal muscle development required further study at the molecular level. Previously Joubert and Tobin C. (56) demonstrated that testosterone treatment of rat levator ani muscle resulted in activation of quiescent satellite cells, and increased replication and the fusion of satellite cells with myofibers. In the rodent, AR role in exercise-induced muscle growth was proven (57), as antiandrogen significantly reduced skeletal muscle gain.
Lee (58) showed that C2C12 myoblast cells stably transfected with AR suppressed skeletal myoblast cell growth and accelerated myoblast cell differentiation and upregulated myogenin expression. We also observed that human AR strongly facilitated C2C12 myotube formation and stimulated increased αSk-actin mRNA steady state levels within 48hr upon exposure to charcoal-stripped differentiation medium, in the absence of exogenous androgens. The aSk-actin promoter was stimulated by AR and SRF; eliminating SRF DNA binding blocked coactivation (Fig 2B) . In proliferating myoblasts reporter gene activity responded to androgens. Thus, sarcomeric contractile protein gene activity was switched on to higher levels by either increasing available AR, or ligand, or both. Recruitment of AR by selective association with SRF via SREs, appears to be a primary mechanism for promoting myogenesis. The capacity of AR to transactivate in the absence of steroids ( Fig  1B versus 2A) in stable transfectants and normally AR-deficient cells, probably results from insufficient endogenous levels of AR-sequestering proteins that would normally retain stably overexpressed AR in the cytoplasm, and prevent AR contact with SRF. Indeed, low level expression of AR results in strong agonist-dependent activation, whereas increasing AR leads to hormone-independent activation (59).
We mapped the physical and functional roles of AR domain interactions with SRF (Fig 5,6,7) . In vitro, GST-fused AR parts capable of SRF recruitment were regions 505-553 (residues N-terminal from DBD, including part of the first Zinc Finger) and 634-804 (part of hinge region and first 2/3 of LBD), were examined, without excluding potential contributions from other regions. In detail, aa505-566, aa505-635, and aa1-627 (all off them include 505-553) bound SRF while the region of aa553-635 showed diminished binding. Our data indicated that aa865-919 (c-terminal 1/3 of LBD) had a negative effect (in the context of aa634-919 and aa505-919) when it was part of GST-AR. By itself it was also unable to bind SRF (Fig 5) . In contrast, aa634-804 bound SRF, demonstrating that LBD, another AR domain region displayed high affinity for SRF. We also found that the AR N-terminus & DBD (1-627) activated
The AR-SRF interaction we describe here is surprisingly different from the one described before between MEF2 and thyroid receptor (63), two proteins homologous to AR (thyroid receptor) and to SRF (MEF2 is a MADS box protein). MEF2 and thyroid receptor interact via their DNA binding domains, while SRF and AR interaction involves different parts of the two proteins. The fact that a number of mutations of AR or SRF disrupt the synergistic effect on skeletal actin promoter activity, while not disrupting activation of promoters responding to either SRF or AR alone, argues against an interaction mediated by mutual expression of a third protein. If AR effects on skeletal actin were due to independent action of AR, then truncated AR 1-627 would still activate skeletal actin promoter activity, at levels comparable to wildtype AR, which it did on the ARdependent MMTV promoter. And if in cultured cells AR-SRF interaction was mediated by a third protein, then it would not require both proteins to be full length; retention of contact surface with that third protein would suffice. This certainly does not exclude the possibility that a large number of other factors and AR coactivators (reviewed 24) might further influence or modulate the AR-SRF interaction. To conclude, myogenic gene expression, as revealed by the activation of the SRF target gene skeletal alpha actin, was regulated by AR and androgen ligand. As SRF is a transcription factor central to the myogenic process and essential for skeletal alpha actin expression, AR shows the potential to activate a host of SRF-dependent genes.
MMTV promoter, as strong as AR full length (Fig 4B) , but failed to synergize with SRF on the skeletal actin promoter, in comparison with the wildtype AR ( Fig  4A) . These data showed that the AR ligand binding domain also associates with SRF. In vitro, LBD interaction with SRF was seen both by recruitment of SRF from the GST-LBD (Fig 5, 634-804) , and by recruitment of LBD by the GST-fused SRF (Fig 7B) . Thus, both the hARLBD and hAR N-terminus plus DBD have the capacity to interact with SRF, and that neither association alone can restore the strength of the interaction of SRF with wildtype hAR.
In cell culture, full length SRF was obligatory for AR to influence skeletal actin promoter activity in nonmyogenic, SRF deficient, CV1 cells. If the AR-SRF cooperative effect was due to titration of a common repressor protein by AR, then AR-SRF coactivation should also occur with SRF mutants, and not only SRF wildtype. Deletions of the fifth exon, MADS box, or N-terminus of SRF, in all cases nullified AR co-stimulatory activity on skeletal actin promoter (Fig 2B) . We also observed that wildtype SRF (Fig 6) bound AR more avidly than any of the SRF mutants. Under closer scrutiny, GST-fused N-terminal SRF sequences interacted with AR LBD, while C-terminal sequences interacted with AR 1-370 (Fig 7) . Thus, these results support the notion that AR and SRF interact through more than one domain and that AR and SRF might actually align antiparallel to each other. This type of association may result in juxtaposition of their transactivation domains, since AR transactivation domain is in AR N-terminus, and SRF transactivation domain in the Cterminus. Interestingly, AR contacts N-and C-terminal ends of the RAP74 subunit of basal transcription factor TFIIF (60), while SRF contacts the central part of RAP74 (61) . This might explain part of AR-SRF synergism as presentation of mutually complementary surfaces to TFIIF, especially because RAP74 was required to relieve SRF-dependent squelching (62). C2C12 myoblasts were plated on 100mm plates at a density of10 6 cells/well. Cells were then brought in either growth medium (GM) or differentiation medium (DM). Cells were also either left untreated or treated with 50nM R1881/ml culture medium. After indicated times cells were harvested and assayed by northern blotting for the 3' untranslated region of the skeletal alpha actin gene. (Panel C) Myoblasts stably transfected with vector pCGNhAR were cultured in Charcoal-stripped DMEM with 20% FCS until 70% confluent, and then brought in Charcoalstripped DMEM with 2% HS for 6, 12, 18 and 24 hours. Rabbit polyclonal anti-AR antibody was used to immunoprecipitate AR from total cell extracts and monoclonal anti-SRF antibody was used for immunoblot. Bacterially expressed GST fusions of AR domains were incubated with reticulocyte-translated, 35 S-labelled SRF, mixed with Glutathione -coated Sepharose beads, and washed five times using PBS. The pellets were taken up in SDS sample buffer and separated using SDS page. The gel was then dried and autoradiographed. Shown here is one of two experiments performed with cell lysates of two different batches. Left is the coomassie stained gel; asterisk (*) indicates GST fusion. 
